Vericel reports record Q1 2023 revenue of $41M; MACI up 32%; raises full-year guidance

Vericel Corp

2023-Q1 EPS reported -$0.16 revenue$41,017,000

Q1 total revenue $41.0M (+14% YoY); MACI revenue $34.2M (+32% YoY); Epicel $6.8M.
Net loss $7.5M ($0.16/diluted share) vs $7.1M loss a year ago; adjusted EBITDA $1.7M (4% rev).
Full-year 2023 revenue guidance raised to $184-$192M from prior $180-$188M; maintains margin guidance.
Cash and investments $139M, no debt; operating cash flow of $7.9M.
MACI arthroscopic delivery program on track for 2024 commercial launch; NexoBrid P&T approvals ahead of goals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.